Skip to main content

Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference

ZUG, Switzerland, April 04, 2024 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today announced the acceptance of two abstracts for presentation at the Consortium of Independent Immunology Clinics (CIIC) Spring 2024 Conference, to be held from April 12-13, 2024, in Arlington, TX.

Presentation details:

  • Title: Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks
    Format: Digital Abstract Display Board
    Date, time: Saturday, April 13, 11:00-11:20 a.m. CDT (12:00-12:20 p.m. EDT)
  • Title: Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial
    Presenter: John Anderson, M.D.
    Format: E-Poster Presentation
    Date, time: Saturday, April 13, 11:20 a.m.-12:00 p.m. CDT (12:20-1:00 p.m. EDT)

The posters and associated presentation slides will be made available on the Investors section of the Pharvaris website at the beginning of the respective presentation sessions at: https://ir.pharvaris.com/news-events/events-presentations.

About Pharvaris
Building on its deep-seated roots in HAE, Pharvaris is a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to treat and prevent HAE attacks. By directly pursuing this clinically proven therapeutic target with novel small molecules, the Pharvaris team aspires to offer people with all sub-types of HAE efficacious, safe, and easy-to-administer alternatives to treat attacks, both on-demand and prophylactically. The company brings together the best talent in the industry with deep expertise in rare diseases and HAE. For more information, visit https://pharvaris.com/.


Contact
Maggie Beller
Executive Director, Head of External and Internal Communications
maggie.beller@pharvaris.com

Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.